A Biomarker Study for Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H Colorectal Patients
Conditions: Colorectal Cancer Sponsors: Geneplus-Beijing Co. Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 24, 2023 Category: Research Source Type: clinical trials
Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Conditions: Advanced Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8 Interventions: Drug: Carboplatin; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Drug: Nab-paclitaxel; Drug: Paclitaxel; Biological: Pembrolizumab; Drug: Pemetrexed; Procedure: Positron Emission Tomography; Other: Quality-of-Life Assessment; Other: Questionnaire Administration Sponsors: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 24, 2023 Category: Research Source Type: clinical trials
Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC
Conditions: Nasopharyngeal Carcinoma Interventions: Drug: without concurrent cisplatin chemotherapy; Drug: with concurrent cisplatin chemotherapy Sponsors: Fujian Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 23, 2023 Category: Research Source Type: clinical trials
ImmunoTHerapy Adjacent to Cervical CAncer (ITHACA) Study
Conditions: Cervical Cancer Interventions: Drug: Anti-PD-1 antibody balstilimab Sponsors: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Dutch Cancer Society; Agenus Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 23, 2023 Category: Research Source Type: clinical trials
NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer
Conditions: Pancreatic Cancer Interventions: Drug: Durvalumab; Drug: Oxaliplatin; Drug: Irinotecan; Drug: Calcium folinate (leucovorin); Drug: Fluorouracil; Drug: Pegylated G-CSF Sponsors: Australasian Gastro-Intestinal Trials Group; The University of New South Wales; Walter and Eliza Hall Institute of Medical Research Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 23, 2023 Category: Research Source Type: clinical trials
FDA Clears Application to Initiate Phase 1 Clinical Study of oral Immunotherapy for the Treatment of Rheumatoid Arthritis
ROCKVILLE, Md., Oct. 19, 2023. - Rise Therapeutics, a biotechnology company engaged in developing novel oral immunotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND)... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 20, 2023 Category: Pharmaceuticals Source Type: clinical trials
Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer
Conditions: Cervical Cancer; Induction Chemotherapy; Immunotherapy Interventions: Drug: Toripalimab Sponsors: Tianjin Medical University Cancer Institute and Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2023 Category: Research Source Type: clinical trials
Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy
Conditions: Cancer; Immune-related Adverse Event Interventions: Other: Medical chart review Sponsors: Duke University Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2023 Category: Research Source Type: clinical trials
Organoid Model Predictive of Response to Immunotherapies
Conditions: Breast Cancer Interventions: Drug: Immunotherapy Sponsors: Indiana University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 16, 2023 Category: Research Source Type: clinical trials
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Advanced Liver Cancer
Conditions: Liver Cancer Interventions: Biological: Autologous Tumor Infiltrating Lymphocytes Sponsors: Zhiyong Huang; Wuhan Elongevity Technology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 16, 2023 Category: Research Source Type: clinical trials
AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer
Conditions: Pancreatic Carcinoma Interventions: Drug: Toripalimab; Drug: Gemcitabine; Drug: Nab paclitaxel; Other: SBRT Sponsors: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School; The First Affiliated Hospital with Nanjing Medical University; Fudan University; Shanghai Changzheng Hospital; The First Affiliated Hospital of Soochow University; Xuzhou Central Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 12, 2023 Category: Research Source Type: clinical trials
PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA): a Prospective Phase 2 Trial
Conditions: Sarcoma; Sarcoma,Soft Tissue; Sarcoma of Bone Interventions: Combination Product: Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT) Sponsors: Ruijin Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 10, 2023 Category: Research Source Type: clinical trials
Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Solid Tumors
Conditions: Metastatic Extracranial Malignant Solid Neoplasm; Radiotherapy; Immune Checkpoint Blockade; Resistance to Immunotherapy Interventions: Radiation: Intestinal Low Dose Radiotherapy-1Gy; Radiation: Intestinal Low Dose Radiotherapy-2Gy; Radiation: Intestinal Low Dose Radiotherapy-3Gy; Drug: PD-1 Inhibitors Sponsors: Chuangzhen Chen Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 10, 2023 Category: Research Source Type: clinical trials
Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy
Conditions: Biliary Tract Cancer; Immune Checkpoint Inhibitor; Predictive Cancer Model Interventions: Drug: Immune Checkpoint Inhibitors Sponsors: Peking Union Medical College Hospital; Geneplus-Beijing Co. Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 9, 2023 Category: Research Source Type: clinical trials
bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma
Conditions: Liver Diseases; Hepatocellular Carcinoma; Immunotherapy; Lenvatinib; Sintilimab Interventions: Procedure: bTAE-HAIC; Drug: Lenvatinib; Drug: Sintilimab Sponsors: Sun Yat-sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 6, 2023 Category: Research Source Type: clinical trials
